Physician profile
Christopher Stalberg
NPI 1346347770
$3,785.80
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $985 · 2021: $1,203 · 2022: $375 · 2023: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $864.60 | 2019-2023 | Otezla, Repatha |
| Pfizer INC. | $262.21 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $257.13 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.53 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Abbott Laboratories | $246.94 | 2019-2023 | Freestyle Libre 2 |
| Abbvie INC. | $210.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $135.85 | 2019-2023 | Breztri |
| Novo Nordisk INC | $122.55 | 2019-2023 | Rybelsus |
| Astellas Pharma US INC | $118.00 | 2020-2021 | |
| Boston Scientific Corporation | $116.28 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $96.44 | 2021-2023 | |
| Lilly USA, LLC | $80.19 | 2020-2023 | Mounjaro, Trulicity |
| Nestle Healthcare Nutrition INC. | $78.99 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $69.66 | 2021-2022 | |
| Edwards Lifesciences Corporation | $66.22 | 2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Stalberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.